PlainPatent

CPC technology class · A61

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Me…

Specific therapeutic activity of chemical compounds or medicinal preparations. 125,535 US utility patents granted 2015–2025, with the leading assignees and year-by-year filing trajectory.

125,535
US patents granted
A61
Parent CPC class
20
Active assignees
+3%
5-yr velocity

The verdict

Specific Therapeutic Activity OF Chemical Compounds OR Me… ranks #10 of 670 CPC technology areas - 125,535 US patents granted since 2015, with filing up 3% over five years.

#10
of 670 CPC technology areas
125,535
US patents granted, 2015–2025
The Regents of the Un…
leading assignee (1,387)
+3%
filing velocity, last 5 yrs
Top assignee: The Regents Of The University Of California (1,387 patents)

CPC subclass A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - covers 125,535 US utility patents granted between 2015 and 2025 according to USPTO PatentsView records, within the broader CPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE). See our CPC classification guide for how the system works.

The competitive landscape in A61P is shaped by 20 distinct companies actively filing in this space. The Regents Of The University Of California leads with 1,387 patents, followed by Novartis Ag at 1,071 grants and Merck Sharp & Dohme Llc at 889.

Filing activity in A61P is up 3% over the past five years versus 2015-2019, a relatively steady filing pace. All counts come directly from USPTO PatentsView and reflect US granted utility patents only.

Is A61P innovation accelerating?

US utility-patent grants per year in A61P, 2015–2025 - recent five years are up 3% versus 2015–2019.

6,0007,0008,0009,00010,00011,00012,000 20152016201720182019202020212022202320242025 7,040

Who leads A61P?

The 12 most active assignees in SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - wider bars mean more grants

patents

What this shows The Regents of the Un… is the most active filer in A61P, holding 1,387 of the 125,535 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.

Source USPTO PatentsView, granted utility patents As of 2015–2025 grant years
View data table
Top patent holders in CPC subclass A61P
Rank Company Patents in A61P
#1 The Regents Of The University Of California 1,387
#2 Novartis Ag 1,071
#3 Merck Sharp & Dohme Llc 889
#4 Bristol-myers Squibb Company 879
#5 Genentech, Inc. 789
#6 The Board Of Regents Of The University Of Texas System 744
#7 Hoffmann-la Roche Inc. 722
#8 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721
#9 Immatics Biotechnologies Gmbh 651
#10 Centre National DE LA Recherche Scientifique 633
#11 Incyte Corporation 605
#12 The Trustees Of The University Of Pennsylvania 594
#13 Janssen Pharmaceuticals, Inc. 592
#14 Pfizer Inc. 549
#15 THE Johns Hopkins University 544
#16 Takeda Pharmaceutical Company Limited 535
#17 Regeneron Pharmaceuticals, Inc. 529
#18 Dana-farber Cancer Institute, Inc. 493
#19 Gilead Sciences, Inc. 492
#20 The Board Of Trustees Of The Leland Stanford Junior University 485

About This Class

CPC subclass A61P belongs to class A61.

125,535 patents were granted in this class between 2015 and 2025.

20 companies actively patent in this space.

Classification System

Cooperative Patent Classification (CPC) is a hierarchical patent classification system used by the USPTO and EPO.

← All Technology Classes Technology Rankings →

Footprint here vs. claim strategy

Each dot is a leading A61P assignee, placed by how many patents it holds in this class (horizontal) against its company-wide average claims per patent (vertical) - a read on whether the class is led by broad-but-shallow filers or focused deep-claim players.

Top 14 A61P assignees by class footprint. Bubble size = patents in A61P. Source: USPTO PatentsView (claim depth is company-wide across all classes).

Top 14 A61P assignees by class footprint. Bubble size = patents in A61P. Source: USPTO PatentsView (claim depth is company-wide across all classes). Scatter plot of 14 data points (bubble-sized by third dimension). 1015202530 4006008001000120014001600 Patents in A61P Avg claims / patent (company-wide) The Regents of the Un…NovartisMerck Sharp & DohmeBristol-myers SquibbGenentechThe Board of Regents…Hoffmann-la RocheThe United States of…Immatics Biotechnolog…Centre National De La…IncyteThe Trustees of the U…Janssen Pharmaceutica…Pfizer
Top 14 A61P assignees by class footprint. Bubble size = patents in A61P. Source: USPTO PatentsView (claim depth is company-wide across all classes).

Frequently Asked Questions

What is CPC class A61P?
CPC subclass A61P covers SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS. It belongs to CPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE), with 125,535 US utility patents granted since 2015.
How many patents have been filed in A61P?
125,535 US utility patents were granted in CPC subclass A61P between 2015 and 2025, based on USPTO PatentsView data.
Which company holds the most patents in A61P?
The Regents Of The University Of California leads A61P with 1,387 patents, making it the most active assignee in this technology area.
How is patent data for A61P collected?
Patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office. It covers all US granted utility patents and assigns CPC codes based on the technology described in each patent.
What is the difference between CPC class and subclass?
A CPC class (e.g., A61) is a broad technology category. Subclasses like A61P provide finer granularity within that category. PlainPatent organizes data at the subclass level (4-character codes) for the most useful view of technology domains.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.